Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.

Saved in:
Bibliographic Details
Title: Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.
Authors: Platz E; Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA., Kaplan LM; Section of Obesity Medicine and Weight Center, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA., le Roux CW; University College Dublin School of Medicine, Dublin, Ireland, and Ulster University, Coleraine, Londonderry, United Kingdom., Wharton S; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Burger S; Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany., Hussain SA; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Brueckmann M; Boehringer Ingelheim International GmbH, Ingelheim, Germany; 1st Department of Medicine, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany., Startseva E; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Fey C; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Kosiborod MN; Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City, Missouri, USA., Bozkurt B; Winters Center for Heart Failure Research, Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, USA. Electronic address: bbozkurt@bcm.edu.
Source: JACC. Heart failure [JACC Heart Fail] 2026 May; Vol. 14 (5), pp. 102780. Date of Electronic Publication: 2025 Nov 03.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101598241 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-1787 (Electronic) Linking ISSN: 22131779 NLM ISO Abbreviation: JACC Heart Fail Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:2213-1787
DOI:10.1016/j.jchf.2025.102780